Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 6/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | CCNK | O75909 | 3/20 | 0.38 |
| ▸ | CCND3 | P30281 | 2/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 3/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17879578 | 0.93 | CDK9 (0.39) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL16204249 | 0.85 | CDK9 (0.41) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL24073506 | 0.82 | CCNA2 (0.44) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL30223473 | 0.82 | CCNA2 (0.44) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL25839416 | 0.78 | LRRK2 (0.43) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL24716303 | 0.77 | KMT2A (0.44) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL19557729 | 0.76 | MAPK8 (0.42) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL17879581 | 0.74 | ALK (0.52) | CDK9CDK2CDK6ALKCDK7 | |
| SCHEMBL2062564 | 0.74 | IGF1R (0.54) | CDK9CCNA2CDK2CCNKCCND3 | |
| SCHEMBL19557698 | 0.73 | CCNA2 (0.38) | CDK9CCNA2CDK2CCNKCCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185753-A1 | DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS | DCK, DPYD, PDCD1 | CDK9 23/4885CCNA2 1133/4885CDK2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.